This animation, created for DOR BioPharma, Inc., depicts the newly developed drug orBec ®. This novel oral, locally acting therapy is tailored to treat the gastrointestinal manifestation of GVHD (Graft-versus-Host disease), the organ system where GVHD is most frequently encountered. orBec® is a two-tablet system containing the highly potent, topically active corticosteroid beclomethasone dipropionate (BDP), and is designed to specifically target and treat upper and lower GI GVHD with reduced systemic immunosupressive side effects.
	back